ZBH · Zimmer Biomet Holdings, Inc. · Financials
$94.86
-1.14 (-1.19%)
At close · Oct 21
Return incl. dividend (before tax)
Market Cap
$18.13B
Shares
190.74M
Volume · Oct 21
1.45M
Avg daily vol (3M)
2.07M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$8.23B
+7.2%
FY2025
Net Income
$705.1M
-22%
FY2025
Gross Margin
76.02%
+0.2pp
FY2010
Operating Margin
13.34%
-3.4pp
FY2025
Diluted EPS
$3.55
-19.9%
FY2025
Operating Cash Flow
$1.7B
+13.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 | FY2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $8.51B | $8.23B | $7.68B | $7.39B | $6.94B | $6.83B | $6.13B | $7.98B | $7.93B | $7.8B | $7.67B | — | — | — | — | — | $4.22B | $4.1B | $4.12B | $3.9B | |
| — | -$289M | -$292.8M | -$218M | -$201.2M | -$164.8M | -$208.4M | -$212.1M | -$226.9M | -$289.3M | -$325.3M | -$355M | — | — | — | — | — | — | — | — | — | |
| — | $2.56B | $2.49B | $2.19B | $2.08B | $2.02B | $1.96B | $1.82B | $2.25B | $2.27B | $2.13B | $2.38B | $1.8B | $1.24B | $1.27B | $1.13B | $1.12B | $1.01B | $990.7M | $997.3M | $875.9M | |
| — | $4.3B | — | — | — | — | — | — | — | — | — | — | — | $3.42B | $3.34B | $3.35B | $3.33B | $3.21B | $3.1B | $3.12B | $3.02B | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 76.02% | 75.81% | 75.8% | 77.53% | |
| — | $442.8M | $458.5M | $437.4M | $458.7M | $406M | $435.8M | $322.8M | $449.3M | $391.7M | $369.9M | $365.6M | $268.8M | $187.4M | $203M | $225.6M | $238.4M | $218.5M | $205.7M | $192.3M | $182.6M | |
| — | $3.43B | $3.26B | $2.93B | $2.84B | $2.76B | $2.84B | $2.71B | $3.34B | $3.38B | $3.1B | $2.94B | $2.28B | $1.75B | $1.75B | $1.81B | $1.83B | $1.76B | $1.73B | $1.7B | $1.52B | |
| — | $679.8M | $665.9M | $591.9M | $561.5M | $526.8M | $529.5M | $512.1M | $584.3M | $595.9M | $603.9M | $565.9M | $337.4M | $92.5M | $78.5M | $97.1M | $93.8M | $92.3M | $93.2M | — | — | |
| — | $1.11B | $1.09B | $996.3M | $951.7M | $926.4M | $937.7M | $898.4M | $1.01B | $1.04B | $1.06B | $1.04B | $712.4M | $375.8M | $358.5M | $363.1M | $359.9M | $340.2M | $337.4M | $275.1M | $230M | |
| — | — | — | — | — | — | $32.1M | — | — | — | $17.3M | $90.7M | $196M | — | — | — | — | — | — | — | — | |
| — | $6.76B | — | — | — | — | — | — | — | — | — | — | $5.53B | $3.64B | $3.55B | $2.3B | $2.31B | $2.29B | $2.09B | $2.03B | $1.89B | |
| — | $7.3B | $7.13B | $6.39B | $6.12B | $6.24B | $5.97B | $6.04B | $6.84B | $7.9B | $7B | $6.85B | $5.53B | $3.64B | — | — | — | — | — | — | — | |
| — | $1.21B | $1.1B | $1.29B | $1.28B | $696.3M | $860.3M | $83.1M | $1.14B | $33.8M | $799.3M | $821.1M | $467.3M | $1.04B | $1.07B | $1.05B | $1.02B | $916.7M | $1.02B | $1.09B | $1.13B | |
| — | — | 13.34% | 16.74% | 17.28% | 10.03% | 12.6% | 1.36% | 14.25% | 0.43% | 10.24% | 10.71% | — | — | — | — | — | 21.72% | 24.88% | 26.45% | 28.93% | |
| — | $2.31B | $2.19B | $2.28B | $2.23B | $1.62B | $1.8B | $981.5M | $2.14B | $1.07B | $1.86B | $1.86B | $1.18B | $1.41B | $1.43B | $1.41B | $1.38B | $1.26B | $1.36B | $1.37B | $1.36B | |
| — | $3.1M | — | — | — | — | — | — | — | — | $2.2M | $2.9M | $9.4M | $11.9M | $15.6M | $15.6M | $10.1M | $3.7M | $1.8M | — | — | |
| — | $17.6M | $25.5M | -$31.1M | -$9.3M | -$128M | $12.2M | $23.8M | -$4.8M | -$15.6M | -$9.4M | -$66.5M | -$36.9M | -$46.7M | — | — | — | — | — | — | — | |
| — | — | $14.7M | -$42.1M | -$18.5M | -$116.6M | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | $933.6M | $830.8M | $1.04B | $1.07B | $403.5M | $499M | -$105.2M | $905.8M | -$271.1M | $464.6M | $399.6M | $153.2M | $939.4M | $1.01B | $990.1M | $978.9M | $860.2M | $998.2M | $1.12B | $1.13B | |
| — | $126.5M | $125.7M | $131.4M | $42.2M | $112.3M | $53.5M | -$96M | -$225.7M | $108.2M | -$1.35B | $95M | $7M | $220.2M | $229.5M | $237.2M | $218.9M | $263.3M | $280.8M | $272.3M | $357.9M | |
| — | $806.7M | $705.1M | $903.8M | $1.02B | $231.4M | $401.6M | -$138.9M | $1.13B | -$379.2M | $1.81B | $305.9M | $147M | $720.3M | $780.4M | $755M | $760.8M | $596.9M | $717.4M | $848.6M | $773.2M | |
| — | — | 8.57% | 11.77% | 13.85% | 3.33% | 5.88% | -2.27% | 14.18% | -4.78% | 23.24% | 3.99% | — | — | — | — | — | 14.14% | 17.52% | 20.59% | 19.84% | |
| — | — | — | — | — | — | $500K | $1.5M | -$100K | -$100K | -$400K | -$1.3M | -$800K | -$1.1M | -$1.8M | -$2.1M | -$800K | — | $0 | $900K | $500K | |
| — | $927.4M | $762.2M | $832M | $1.01B | $222.6M | $467.8M | -$194.8M | $1.08B | -$440.5M | $2.17B | $200.1M | -$220.6M | $457.4M | $813.2M | $827.6M | $711.3M | $559.3M | $836M | $798.3M | $854.3M | |
| USD/shares | — | $4.12 | $3.56 | $4.45 | $4.91 | $1.10 | $1.93 | -$0.67 | $5.52 | -$1.86 | $8.98 | $1.53 | $0.78 | $4.26 | $4.60 | $4.32 | $4.05 | $2.98 | $3.34 | $3.73 | $3.28 |
| USD/shares | $8.47 – $8.59* | $4.12 | $3.55G | $4.43G | $4.88G | $1.10G | $1.91G | -$0.67 | $5.47 | -$1.86 | $8.90 | $1.51 | $0.77 | $4.20 | $4.54 | $4.29 | $4.03 | $2.97 | $3.32 | $3.72 | $3.26 |
| shares | — | — | 198M | 203.1M | 208.7M | 209.6M | 208.6M | 207M | 205.1M | 203.5M | 201.9M | 200M | 187.4M | 169M | 169.6M | 174.9M | 187.6M | 200M | 215M | 227.3M | 235.5M |
| shares | — | — | 198.7M | 203.9M | 209.7M | 210.3M | 210.4M | 207M | 206.7M | 203.5M | 203.7M | 202.4M | 189.8M | 171.7M | 171.8M | 176M | 188.7M | 201.1M | 215.8M | 228.3M | 237.5M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2007–FY2025: $8.14B in buybacks, $2.49B in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Latest reported total
USD 7,479,000,000
As of Jun 30, 2026
Tracked instruments
0
Loans, facilities and note series
Annual baseline
—
Latest approved annual total
Reported total debt history
| As of | Reported label | Amount | Source |
|---|---|---|---|
| 2026-06-30 | outstanding debt | USD 7,479,000,000 |
10-Q filed 2026-08-05
At June 30, 2026, we had outstanding debt of $7,479.0 million, of which $1,201.5 million was classified as current debt. Our current debt consists of $571.5 million of senior notes that mature on December 13, 2026, $600.0 million of senior notes that mature on February 19, 2027 and $30.0 million outstanding on our Uncommitted Credit Facility which we expect to repay within the next year. We believe we can satisfy these debt obligations with cash on hand, cash generated from our operations, by issuing new debt and/or by borrowing on our committed revolving credit facilities. |
| 2026-03-31 | outstanding debt | USD 7,471,000,000 |
10-Q filed 2026-05-01
At March 31, 2026, we had outstanding debt of $7,471.0 million, of which $1,175.9 million was classified as current debt. |
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of long-term debt | 2026-06-30 | USD 1,201,500,000 | 10-Q filed 2026-08-05 |
| Noncurrent debt carrying amount | 2026-06-30 | USD 6,277,500,000 | 10-Q filed 2026-08-05 |
4 filing observations remain unmatched and are excluded from instrument histories.
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
2 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.96×
Peer median 3.87×
EV/EBIT
20.91×
Peer median 25.64×
P/E (TTM)
23.07×
Peer median 29.90×
Peer medians compare against the 27 similar-size Medical Devices companies (of 156 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Americas | $5,144,600,000 | $4,794,800,000 | $4,624,100,000 | $4,295,500,000 | $4,102,100,000 | $3,699,500,000 | $4,875,800,000 | $4,837,200,000 |
| EMEA | $1,828,800,000 | $1,691,100,000 | $1,592,400,000 | $1,456,500,000 | $1,477,200,000 | $1,237,300,000 | $1,623,100,000 | $1,801,900,000 |
| Asia Pacific | $1,258,100,000 | $1,192,800,000 | $1,177,700,000 | $1,187,800,000 | $1,248,000,000 | $1,190,700,000 | $1,359,500,000 | $1,293,800,000 |
| United States | — | — | — | — | $3,853,900,000 | $3,507,700,000 | $4,592,100,000 | $4,560,000,000 |
| Non Us | — | — | — | — | $2,973,400,000 | $2,619,800,000 | — | — |
| Americas and Global Businesses | — | — | — | — | — | $4,479,000,000 | $5,035,300,000 | $5,000,400,000 |
| Americas Orthopedics | — | — | — | — | $4,102,100,000 | $3,699,500,000 | $4,148,800,000 | — |
| Americas Spine and Global Dental | — | — | — | — | $882,000,000 | $779,500,000 | $886,500,000 | — |
| Immaterial Product Category Operating Segments | — | — | — | — | — | — | $1,168,500,000 | $1,187,300,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Knees | $3,322,300,000 | $3,173,500,000 | $3,038,400,000 | $2,778,300,000 | $2,647,900,000 | $2,378,300,000 | $2,780,600,000 | $2,773,700,000 |
| SET | $2,150,200,000 | $1,865,700,000 | $1,752,600,000 | $1,696,700,000 | $1,727,800,000 | $1,525,600,000 | $1,652,500,000 | $1,401,200,000 |
| Hips | $2,093,500,000 | $1,999,100,000 | $1,967,200,000 | $1,894,900,000 | $1,856,100,000 | $1,750,500,000 | $1,931,500,000 | $1,918,900,000 |
| Technology and Data, Bone Cement and Surgical | $665,600,000 | $640,300,000 | $636,000,000 | $570,000,000 | $595,500,000 | $473,100,000 | $595,800,000 | $664,000,000 |
| Dental and Spine | — | — | — | — | — | — | $1,021,800,000 | — |
| Dental | — | — | — | — | — | — | $414,000,000 | — |
| Dental Spine and CMFT | — | — | — | — | — | — | $1,161,300,000 | $1,175,100,000 |
| Spine and CMF | — | — | — | — | — | — | $747,300,000 | — |
Key facts
CIK
1136869
CUSIP
98956P102
13F (30d)
179 filings
156 filers
Visit website
Investor relations